Use of positron emission tomography in anticancer drug development

被引：21

作者：

Aboagye, EO ^{[1
]}

Price, PM ^{[1
]}

机构：

[1] Hammersmith Hosp, Dept Canc Med, Fac Med, Imperial Coll Sci Technol & Med,PET Oncol Grp, London, England

来源：

INVESTIGATIONAL NEW DRUGS | 2003年 / 21卷 / 02期

关键词：

positron emission tomography; pharmacokinetics; pharmacodynamics; modeling; anticancer; drug development;

D O I：

10.1023/A:1023521412787

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[C-11]thymidine, [F-18]fluorodeoxyglucose, (H2O)-O-15, (CO)-O-15, and receptor ligands.

引用

页码：169 / 181

页数：13

共 50 条

[31] POSITRON EMISSION TOMOGRAPHY - TECHNOLOGY AND USE
HICHWA, RD
[J]. MEDICAL PHYSICS, 1987, 14 (03) : 506 - 506
[32] Positron emission tomography and single-photon emission computed tomography in central nervous system drug development
Brooks D.J.
[J]. NeuroRX, 2005, 2 (2): : 226 - 236
[33] Positron emission tomography and its use to image the occupancy of drug binding sites
Gatley, SJ
Volkow, ND
Fowler, JS
Ding, YS
Logan, J
Wang, GJ
Gifford, AN
[J]. DRUG DEVELOPMENT RESEARCH, 2003, 59 (02) : 194 - 207
[34] Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development
Burns, HD
Hamill, TG
Eng, W
Francis, B
Fioravanti, C
Gibson, RE
[J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (04) : 388 - 394
[35] In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography
Aboagye, EO
Price, PM
Jones, T
[J]. DRUG DISCOVERY TODAY, 2001, 6 (06) : 293 - 302
[36] Positron emission tomography agents for central nervous system drug development applications
Mason, NS
Mathis, CA
[J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 49 - 68
[37] Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring
Piel, Markus
Vernaleken, Ingo
Roesch, Frank
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (22) : 9232 - 9258
[38] The use of positron emission tomography in cerebrovascular disease
Powers, WJ
Zazulia, AR
[J]. NEUROIMAGING CLINICS OF NORTH AMERICA, 2003, 13 (04) : 741 - +
[39] USE OF POSITRON EMISSION TOMOGRAPHY IN RHEUMATOLOGY PRACTICE
Isik, O. Ozdemir
Isgoren, S.
Yazici, A.
Cefle, A.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1551 - 1552
[40] Positron emission tomography for use in microdosing studies
Wagner, Claudia Christina
Mueller, Markus
Lappin, Graham
Langer, Oliver
[J]. CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2008, 11 (01) : 104 - 110

← 1 2 3 4 5 →